Raising the ‘Good’ Oxidants for Immune Protection

Alexia Dumas and Ulla G. Knaus*

Conway Institute, School of Medicine, University College Dublin, Dublin, Ireland

Redox medicine is a new therapeutic concept targeting reactive oxygen species (ROS) and secondary reaction products for health benefit. The concomitant function of ROS as intracellular second messengers and extracellular mediators governing physiological redox signaling, and as damaging radicals instigating or perpetuating various pathophysiological conditions will require selective strategies for therapeutic intervention. In addition, the reactivity and quantity of the oxidant species generated, its source and cellular location in a defined disease context need to be considered to achieve the desired outcome. In inflammatory diseases associated with oxidative damage and tissue injury, ROS source specific inhibitors may provide more benefit than generalized removal of ROS. Contemporary approaches in immunity will also include the preservation or even elevation of certain oxygen metabolites to restore or improve ROS driven physiological functions including more effective redox signaling and cell-microenvironment communication, and to induce mucosal barrier integrity, eubiosis and repair processes. Increasing oxidants by host-directed immunomodulation or by exogenous supplementation seems especially promising for improving host defense. Here, we summarize examples of beneficial ROS in immune homeostasis, infection, and acute inflammatory disease, and address emerging therapeutic strategies for ROS augmentation to induce and strengthen protective host immunity.

Keywords: reactive oxygen species, NADPH oxidase, microbiota, host defense, immune signaling, redox medicine, lactobacilli, glucose oxidase

INTRODUCTION

Reactive oxygen species (ROS) is a generic term referring to oxygen-derived compounds capable of reacting with biological molecules through an oxidation-reduction (“redox”) mechanism. ROS include a set of highly reactive radicals (e.g., superoxide anion, hydroxyl radical) as well as non-radical species [e.g., hydrogen peroxide (H₂O₂)] produced enzymatically or chemically in eukaryotic and prokaryotic cells. In mammals, one of the main intracellular sources of ROS is the mitochondrial electron transport chain (ETC) during the establishment of the proton-motive force. Premature electron leakage to molecular oxygen occurs mainly from complex I and III of the ETC during the serial transfer of electrons, causing superoxide formation that is converted to H₂O₂ by superoxide dismutase (SOD) (1, 2). In contrast to ROS generation as by-product of aerobic metabolism, of oxidation of fatty acids or proteins, or of enzyme-substrate reactions (e.g., xanthine oxidase, lipoxygenase, cyclooxygenase, monoamine oxidase), the NADPH oxidase family (NOX/DUOX) is solely

*Correspondence: Ulla G. Knaus ulla.knaus@ucd.ie

Specialty section: This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology

Received: 20 April 2021  Accepted: 18 May 2021  Published: 04 June 2021

Citation: Dumas A and Knaus UG (2021) Raising the ‘Good’ Oxidants for Immune Protection. Front. Immunol. 12:698042, doi: 10.3389/fimmu.2021.698042
transcriptional activation of antioxidant genes is the KEAP1-signaling also drives the antioxidant response to prevent molecular oxygen to superoxide or H$_2$O$_2$. Seven oxidase isoforms have been characterized in humans, differing in their catalytic core (NOX1-5 and DUOX1-2), their requirement for additional components for complex stabilization and/or enzyme activation, their subcellular localization and in tissue specificity (3, 4). The NADPH oxidase prototype is the NOX2 enzyme, an essential superoxide source for pathogen defense by neutrophils and macrophages. The rapid increase of superoxide (‘respiratory burst’) is accompanied by the formation of dismutation and adduct products, including hypochlorite (generated by myeloperoxidase, H$_2$O$_2$ and chloride ion) and peroxynitrite (spontaneous reaction of superoxide with nitric oxide), both strongly oxidizing and nitrating compounds that drive pathogen killing in concert with activated proteases (5). Tight regulation of ROS generation is essential, as ample and uncontrolled production of highly reactive species over an extended time period will cause irreversible redox modifications on biomolecules, thus promoting oxidative damage.

ROS is not only produced during host defense or in proinflammatory situations. Superoxide and H$_2$O$_2$ are continuously generated, converted, and degraded in physiological conditions (6, 7). H$_2$O$_2$ as a key intracellular messenger mediating signal transduction in all cell types maintains homeostasis and physiological host responses (8, 9). H$_2$O$_2$-initiated redox signaling is essential for basic cellular processes (e.g., proliferation, migration, secretion), thereby supporting complex functions in mucosal immunity (e.g., barrier integrity, host-microbiota communication, host defense, chemokine/cytokine generation, wound repair), driving innate immune functions and regulating adaptive immunity. By aquaporin-facilitated diffusion across the plasma membrane or by release from intracellular organelles (e.g., redoxosomes, microvesicles, mitochondria), H$_2$O$_2$ mediates directly or more commonly via redox relays the reversible oxidation of distinct amino acids, modifying the structure and function of targeted proteins and consequently the activation state of the associated signaling pathways. In mammals, thiol oxidation of certain reactive cysteine residues occurs within redox-sensitive proteins, including phosphatases and tyrosine kinases, leading to activation or inactivation of the targeted protein (2, 10). Redox signaling also drives the antioxidant response to prevent excessive ROS production. A notable conduit for transcriptional activation of antioxidant genes is the KEAP1-NRF2 pathway. H$_2$O$_2$-mediated oxidation of the redox-sensitive adaptor KEAP1 disrupts its cytosplasmic complex with NRF2, promoting nuclear translocation of newly synthesized NRF2 which will bind to antioxidant response elements (ARE) located in the promoter region of NRF2 target genes such as NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HMOX1), glutamate-cysteine ligase (GCL) and glutathione S transferases (GSTs) (11, 12).

Coupled oxidant-antioxidant pathways have been conserved throughout evolution. For example, in bacteria dedicated transcriptional regulators (e.g., OxyR, OhrR, PerR, SoxR) sense ROS/RNS in order to induce an appropriate detoxification response (e.g., radical scavenging and metal sequestrating systems), and to maintain intracellular oxidant levels within a safe limit (13, 14). The H$_2$O$_2$ sensing transcriptional regulator OxyR is a well-studied example in mainly Gram-negative bacteria. When intracellular H$_2$O$_2$ exceeds a certain threshold in Escherichia coli (~0.1-0.2 μM (15, 16)), oxidation of OxyR on two cysteine residues prompts a conformational change due to intramolecular disulfide bond formation, activating the expression of OxyR-dependent antioxidant defense genes (17, 18). At mucosal surfaces physiological H$_2$O$_2$ levels mediate the intricate redox communication between commensal microorganisms and the host barrier tissue. For instance, bacteria can induce or hinder physiological host signaling, either by releasing H$_2$O$_2$ in the vicinity of host epithelia (e.g., lactobacilli) or by altering host enzyme-mediated ROS generation via secreted compounds or physical interaction with epithelial barrier cells (19–21). Likewise, H$_2$O$_2$ released by host cells can alter bacterial signaling in response to a pathogenic insult, particularly in low oxygen environments (22, 23).

It is important to distinguish these beneficial redox-mediated mechanisms supporting health from conditions promoting supraphysiological level of ROS and the resulting oxidative damage. To ensure physiological conditions, the activation of NADPH oxidases is usually regulated by multiple inputs (e.g., transcriptional, posttranslational, metal ions, nucleotides) and ROS generation is coupled with decomposing and scavenging systems (e.g., catalase, peroxidases, antioxidants) (2, 4, 21, 24). Ongoing perturbation of ROS levels, either at high or low range, has been associated with various pathophysiological states. Persistent increase of highly reactive species (e.g., superoxide anion, hydroxyl radical, peroxynitrite) has been associated with chronic inflammatory and hyperglycemic (e.g., rheumatoid arthritis, inflammatory bowel diseases, type 2 diabetes), tumorigenic and neurological (e.g., Parkinson’s, Alzheimer’s) diseases. Therapeutically decreasing ROS levels by non-specific enzyme inhibitors or antioxidants has been pursued for many decades (25, 26). However, the ill-defined and generalized action of these molecules limits their efficacy and, in some cases, exacerbated the underlying condition (27–32). More targeted approaches, namely inhibition of a specific ROS source, may provide more benefit. Conversely, permanently decreased ROS generation due to loss-of-function variants in genes encoding for NADPH oxidases or other ROS sources, or in genes providing an essential upstream trigger for a superoxide/H$_2$O$_2$ generating enzyme, have been linked to various pathologies, including recurrent microbial infections, chronic inflammatory diseases, and autoimmunity (33). In this case, a strategy to restore or enhance ROS may prove beneficial.

Understanding redox regulation of vital physiological processes and how alterations initiate or perpetuate disease is important for developing new therapeutic avenues. In addition to traditional therapeutic strategies aimed at counteracting excessive ROS, contemporary approaches should include preservation or even the elevation of certain oxygen metabolites for physiological purposes. This review will provide selected examples of beneficial ROS in protective host
immunity and will discuss emerging therapeutic strategies to preserve or augment ROS with the aim of re-establishing homeostasis and promoting host protection.

**IMPORTANCE OF OXIDANTS IN PROTECTIVE IMMUNITY**

**Homeostatic Redox Signaling**

Physiological ROS levels modulate many immune functions by redox-sensitive signaling. Not only H₂O₂, but also related second messengers such as nitric oxide and possibly peroxynitrite control signaling responses and thus these short-lived molecules represent an integral part of immune regulation (34–37). All redox-regulated pathways show analogous features, namely inhibitory or activating modifications on proteins and lipids (10, 38, 39), and are conserved across different cell types and organisms. Redox modifications can constrain or stimulate signaling pathways. An example for inhibitory oxidative modifications is dual specificity phosphatase 1 (DUSP1) which will be degraded after oxidation or S-glutathionylation of an active site cysteine, resulting in prolonged MAPK-induced proinflammatory gene transcription (40). Reversible oxidative inactivation of protein tyrosine phosphatase 1B (PTP1B) amplified interleukin (IL)-4 receptor activation (41). On the other hand, redox-dependent oxidation of two cysteine residues in the tyrosine kinase SRC caused structural changes that impacted regulatory tyrosines, enabling SRC kinase activation (42). In airway epithelial cells, epidermal growth factor receptor signaling was linked to activation of the NADPH oxidase DUOX1 and subsequent SRC oxidation (43). Kinase activation can also occur by oxidation-driven dissociation of an inhibitor-protein kinase complex as demonstrated for the complex between thioredoxin and apoptosis signal-regulating kinase 1 (ASK1) (44). The liberated form of ASK1 will then form multimeric complexes with other signaling mediators and positively regulate JNK/p38 MAPK pathways, while itself being further controlled by dephosphorylation and deubiquitination (45). More examples and details on redox regulation of signaling pathways can be found in recent reviews (1, 46).

The initiation of redox signaling occurs mainly after ligand stimulation of receptors (e.g., Toll-like receptors (TLR), G protein-coupled receptors (GPCR), NOD-like receptors (NLR), Fc receptors, chemokine and cytokine receptors, and others) and may include one or several ROS sources concomitantly or consecutively, depending on the context. For instance, redox regulation triggered by TGF-β involves the NADPH oxidase NOX4 as well as mitochondrial ROS (mROS) (47). NADPH oxidases seem to be closely associated with TLR-stimulated pathways where oxidase deficiency either inhibits or enhances host cell responses. Loss of NOX1 in smooth muscle cells increased TLR2-mediated MIP-2 generation but impeded matrix metalloprotease 2 secretion and directed cell migration (48). In epithelial cells NOX4 was reported to associate with TLR4, regulating the transcription factor NF-kB (49). Loss-of-function mutations in any of the five subunits comprising the NOX2 complex cause the inherited immunodeficiency chronic granulomatous disease (CGD) (33, 50). One of the effects of CGD in the immune system is the altered responsiveness to TLR ligands, resulting in augmented cytokine generation and hyperinflammation. Neutrophils, monocytes, and dendritic cells isolated from CGD patients or Nox2 deficient mice generated increased levels of cytokines upon TLR2 or TLR4 stimulation (51–54). A hyperinflammatory phenotype with excessive secretion of pro- and anti-inflammatory cytokines was also observed in CGD B lymphocytes stimulated with TLR7 and TLR9 agonists (55). This cytokine overproduction was associated with hyperactivation of p38 MAPK signaling, which may indicate loss of inhibitory feedback signaling, likely involving phosphatases, when the NOX2 enzyme is inactivated. Increased levels of IFNγ and IL-18 in CGD patient tissues was in part traced to macrophages remaining in a proinflammatory M1 state (56). Innate immune cells derived from CGD patients or mice also showed an exuberant IL-1 response to various inflammasome activating stimuli, while the NRF2-controlled antioxidant response was dampened (57–59). The hyperinflammatory CGD phenotype in mice and man is intensified by increased neutrophil recruitment to sites of infection and tissue damage, which was recently linked to feed-forward amplification of neutrophil generated leukotriene B4 upon pulmonary zymosan challenge (60). Hence, deficiency in NOX2 enzyme activity creates a proinflammatory environment that is associated with several chronic inflammatory conditions and can predispose to autoimmune disease (61). The molecular mechanisms underlying various facets of CGD hyperinflammation are still not resolved, but NOX2-derived superoxide seems to be required for the precise regulation of many immune cell functions including gene transcription, autophagy, efferocytosis, and dendritic cell-mediated antigen presentation (61–64).

In recent years, the role of mROS signaling in regulating both innate and adaptive immunity received increased attention (65, 66), although in many cases molecular mechanisms are not well characterized and mROS participation in signaling is mainly inferred by using mitochondria-targeted ROS probes and/or antioxidants. Chandel and coworkers linked early on a TNF receptor-TRAF pathway to an increase in mROS (67), and by now many different stimuli are recognized as triggers of physiological mROS generation (6). Here we summarize recent insights into mROS-mediated immune cell responses. Signaling cascades driven by TLRs stimulate not only NADPH oxidase activity, but also via TRAF6 the mitochondrial matrix protein ECSIT that stimulates superoxide production from ETC complex I (68). Others reported recently that pro-inflammatory cytokine secretion by Listeria monocytogenes-infected macrophages is contingent on mROS-induced disulfide bond formation in the IKK complex regulator NEMO (69). Activation of the NLRP3 inflammasome by pathogen-associated or danger-associated molecular patterns (PAMPs/DAMPs) is controlled by mROS, resulting in release of the proinflammatory cytokines IL-1β and IL-18 (70, 71). The precise sequence of events that may include a
transcriptional priming step, oxidized mitochondrial DNA, and mROS-dependent interaction of NLRP3 with thioredoxin-interacting protein is not yet fully established (72). In macrophages NLRP3 inflammasome activation required xanthine oxidase generated superoxide upstream of mROS generation (73), while studies in superoxide deficient peripheral blood mononuclear cells derived from CGD patients revealed that NOX enzymes are not required for NLRP3-mediated IL-1β secretion (74, 75). Cytosolic retinoic acid-inducible gene I (RIG-I)-like receptors such as RIG-I and MDA5 sense and bind distinct features of viral RNA, then oligomerize, and associate with the adaptor protein MAVS at outer mitochondrial membranes and mitochondria-associated membranes. Oligomerization of MAVS recruits several effector proteins to form the MAVS signalosome, driving IRF3/IRF7-mediated transcription of type I/III interferon and NF-κB-induced proinflammatory cytokine expression. MAVS expression has been linked to NOX2 generated superoxide (76), while others reported functional interactions involving MAVS aggregation, mROS generation, and the cytochrome c oxidase component COX5B that couple the antiviral response to autophagy (77). The NLR family member NLRX1 cannot only interact with MAVS at the outer mitochondrial membrane but is also localized within the matrix and inner membrane of mitochondria where interaction with the ETC complex III associated protein UQRC2 promotes mROS generation, thereby stimulating transcription factors and JNK MAP kinase (78). The signaling function of the immune response-induced mitochondrial interactome is clearly connected to mROS generation, in physiological and pathophysiological conditions, and many more aspects of mitochondrial immune signaling and connections between different ROS sources influencing each other in these processes can be expected in the future.

Mucosal Barriers and Oxidants

The mucosal immune system in lung, gastrointestinal tract (GIT), urogenital tract, oral and nasal passages employs structural, chemical and immunological barriers to control the interaction with the adjacent microorganism- and noxious substance-rich environment. The importance of mucosal barriers as host defense mechanism is reflected in these multiple layers of protection together with the constant renewal of barrier epithelia, specialized protective measures such as secretion of mucus or surfactant, and highly efficient repair mechanisms. Superoxide and H$_2$O$_2$, generated by host enzymes or commensal bacteria, are crucial for various aspects of mucosal barrier maintenance as outlined here in selected examples.

The structural integrity of mucosal epithelial barriers relies on intercellular junctions, in particular tight junctions, and after a breach occurred, on rapid proliferation and migration of epithelial cells for wound repair. ROS regulate cytoskeletal dynamics such as oxidative modification of β-actin and tubulin, RhoA GTPase activation and deactivation depending on the context, redox-induced integrin and focal adhesion kinase (FAK) activation and oxidative modifications on other proteins involved in cytoskeletal rearrangements (79, 80). As many of these physiological processes have not yet been conclusively linked to a particular ROS source or studied in epithelial barriers, we will present here only results that identified the enzyme involved, were obtained by multiple approaches and if possible in vivo. In the GIT, superoxide produced by NOX1 controls colon epithelial cell proliferation and migration, in part by enhancing FAK phosphorylation due to oxidative inactivation of the tyrosine phosphatases LMW-PTP and SHP-2 that will initiate focal adhesion turnover, accelerate cell migration, and improve wound closure (81–85). Others reported NOX1-mediated oxidation of nucleoredoxin that released suppression of the canonical WNT-β-catenin pathway, resulting in transcription of growth promoting genes (86, 87). In airway epithelial cells DUOX was localized at the leading edge of migrating cells, augmenting wound healing (88). DUOX1 generated H$_2$O$_2$ regulated cell migration and epithelial repair in cells and in a naphthalene airway injury model by promoting epidermal growth factor receptor (EGFR)-STAT3 signaling (89, 90).

An important part of the physical gut barrier is the protective mucus layer, either single-layered in the small intestine and pulmonary tract, or 2-layered with a dense, impenetrable layer followed by a loose layer in the colon. Mucus is secreted and continuously renewed by goblet cells and is composed of mainly MUC2 mucin in the intestine, MUC1, MUC5AC and MUC6 mucins in the stomach, and MUC5AC and MUC5B mucins in the lung epithelium (91). NADPH oxidase generated H$_2$O$_2$ has been linked to intestinal mucin granule release by pathways involving endocytosis, autophagy, and NLRP6 signaling (92, 93).

A severe colonic phenotype with partial loss of the dense mucus layer was only observed in mice with combined inactivation of Nox1-3 but not in single oxidase knockout mice (94), likely due to in vivo compensation by another oxidase (or ROS source) or by H$_2$O$_2$ producing lactobacilli colonizing the mucus layer. In the airways EGFR and IL-13 signaling promoted mucin gene induction (MUC5AC, CLCA1) via DUOX1 (95, 96), while others reported a TLR5-DUOX2 pathway regulating MUC5AC expression in nasal epithelium (97).

The structural reinforcement of the intestinal barrier is accompanied by chemical and immunological secretions. Immunological secretions are immunoglobulin A (sIgA) and various other antimicrobial factors including lysozyme, regenerating islet-derived proteins 3, and cationic peptides such as cathelicidins or defensins. Cationic peptides range from α-helical (e.g., LL-37) to β-sheet (e.g., β-defensins) conformation or random-coil structures and exert their activity by bacterial membrane disruption and immunomodulatory effects on host cells (98, 99). While their synthesis or secretion has not been linked to a ROS source, the proper folding of some bioactive cysteine-rich peptides such as β-defensin 3 require the oxidative formation of several disulfide bridges (100). Lipocalin-2 (LCN-2), secreted by intestinal epithelial cells or released from neutrophil secondary granules, is often used as a biomarker of inflammatory processes, but also limits bacterial growth by binding iron-loaded siderophores (101, 102). A recent report connected LCN-2 expression via a typical 1κBζ-dependent gene
transcription to NOX1 activity in colonic epithelial cells and mice (103).

Mucosal barriers generate and release chemical compounds such as superoxide, H$_2$O$_2$, nitric oxide and peroxynitrite when pathogens or danger-associated molecules trigger host cell responses. These chemicals may also be released constitutively at low concentrations as repellent against commensal communities, promoting a mutualistic host-microbiota relationship essential for immunity (21, 104). This is supported by reports that enteric bacteria regulate NADPH oxidase activity by relatively undefined pathways (85, 105, 106), and vice versa that ROS generated by mitochondria or epithelial cells control the microbial population, thereby limiting the access of the microbiota to the immune compartment (19, 107). This scenario likely takes place in the small intestine with its loose, single mucus layer and may involve the oxidase DUOX2. DUOX2 expression is upregulated by microbiota, and its localization at the apical surface of villi is ideally suited for H$_2$O$_2$ release, thereby reinforcing the separation of host and microbial communities (19). Additionally, peroxynitrite generated by the combined activation of NOX1 and NOS2 may participate in the control of ileal homeostasis (108, 109).

Similarly, H$_2$O$_2$ release by DUOX1/DUOX2 and subsequent lactoperoxidase-mediated conversion to secondary oxidants (i.e., HOSCN) may repel bacteria in the airways (110). Influenza A virus (IAV) infection stimulated H$_2$O$_2$ release from air-liquid interface cultured primary human airway epithelial cells in a calcium/flavoenzyme dependent manner, suggesting DUOX activation (111).

Chemical messengers are ideally suited to relay signals from the host to the microbiota and vice versa. This interkingdom communication will shape microbiota diversity and composition and provides a stimulus for homeostatic barrier host responses. While aberrant ROS production in inflammatory disease will increase the abundance of certain bacterial communities and may lower overall diversity, decreased levels or loss of NADPH oxidase-generated ROS, as observed in certain patient populations, will also favor dysbiosis, indicating that a tightly balanced mucosa-associated microenvironment is indispensable for gut homeostasis. While CGD is mainly associated with recurrent life-threatening infections, 40-50% of these patients will develop inflammatory bowel disease with some features of Crohn’s disease. When comparing the microbiota of CGD patients to healthy individuals an increased abundance of mucus foraging Ruminococcus gravis was noted (112). This study included only a limited number of patients (10 individuals) and might be skewed due to the required antibiotic maintenance of these patients. In a CGD mouse model (i.e., p47phox deficiency) the microbiome signature was altered by high abundance of Akkermansia muciniphila (113). This mucolytic bacterium is considered a beneficial probiotic, but can also disturb mucus homeostasis in the host, thereby acting as a pathobiont or aggravating inflammation induced by intestinal pathogens (114–116). In the ileum of Nox1 knockout mice increased abundance of Bifidobacteria and Turicibacter was detected (117). Global inactivation of the oxidases Nox1-3 in mice (Cyba$^{+/+}$) resulted in increased abundance of Proteobacteria, Ruminococcaceae and Mucispirillum schaelederi (94). An increase of M. schaelederi was also noted in mice with combined Nod2/Nox2 deficiency (118). This mucus dwelling bacterium interfered with Salmonella enterica serovar Typhimurium virulence factor expression and decreased pathogen invasion in wildtype mice (119), but it also promoted inflammation in Nod2/Nox2 double knockout mice. Inactivation of all four murine Nox enzymes by global or intestinal epithelium restricted deletion of the essential Nox partner protein p22phox (Cyba$^{+/+}$, Cyba$^{-/-}$) induced compensatory upregulation of H$_2$O$_2$ producing lactobacilli as a host protective, mutualistically beneficial mechanism (120). These results in mice suggest that H$_2$O$_2$ generation, mucus changes and overgrowth of mucus-dwelling or mucolytic bacteria are closely linked. Thus, ROS maintain and protect the stable microenvironment required for balanced and interconnected host-commensal cooperation and homeostatic barrier function.

**Specialized Roles of Oxidants in Innate Immune Cells**

**Macrophage Polarization**

The versatile role of ROS in regulating the intracellular signalosome in a constantly evolving microenvironment underpins their role in promoting polarization of immune cell populations and supporting specialized functions. A pertinent example is altering the polarization and activation state of macrophages in the broad categories of M1 (classical) and M2 (alternative), categorized by a proinflammatory, host defense connected phenotype versus an anti-inflammatory, tissue remodeling phenotype (121). NOX2 is expressed in M1 and M2 macrophages and regulates the transition between phenotypes in a context dependent manner. Nox2 deficient bone marrow derived macrophages (BMDM) upregulated STAT3 activation and anti-inflammatory cytokine expression (i.e., IL-10), while others reported no differences between wildtype and Nox2 knockout M2 macrophages (122, 123). Conflicting results in the literature stem likely from the range of protocols used for macrophage differentiation (e.g., conditioned media versus recombinant GM-CSF or M-CSF for various time periods, LPS content of fetal bovine serum) and the inclusion or omission of further Th1 or Th2 type polarization. M1 polarized BMDM express not only Nox2 but also Nox1 (124). When M-CSF differentiated BMDM or peritoneal macrophages derived from wildtype, Nox1, Nox2 or Nox1/Nox2 knockout mice were further polarized by LPS+IFN$\gamma$ or IL-4+IL-10, only Nox1/Nox2 deficient macrophages exhibited reduced M2-type polarization while M1 polarization and pro-inflammatory functions were preserved (123). Expression of Nox4 in macrophages and its downstream effects seem to be determined by the microenvironment. Using a similar M1/M2 polarization protocol as described above Helfinger and coworkers observed in Nox4 deficient mouse macrophages amplification of the M1 phenotype, suggesting an anti-inflammatory role for Nox4 (125). On the other hand, NOX4 expression was induced in human monocyte-derived
Dendritic Cell Function

Dendritic (DC) cells are antigen-presenting cells that are essential for inducing naïve T cell activation and effector differentiation. After taking up antigens and microbes by phagocytosis or endocytosis DCs generate MHC peptide complexes. For activation of CD4+ T helper cells, antigens are degraded in lysosomes for MHC class II presentation, while DCs generate MHC peptide complexes for presentation in MHC class I by cross-presentation that occurs mainly by their functional phenotype with N1 considered pro-inflammatory and anti-tumorigenic, and N2 pro-tumorigenic. A role for ROS in this phenotypic conversion has not yet been defined.

Host Defense and Oxidants

Respiratory and intestinal barrier epithelia are the first line of defense against airborne or foodborne pathogens. When the initial protective mechanisms (e.g., colonization resistance, antimicrobial secretions, mucus layer) have failed, epithelial sensing pathways will be activated. In the mucosal compartment, sensing of conserved microbial motifs by epithelial cells induces ROS production due to upregulation and/or activation of mucosal NADPH oxidases (e.g., DUOX1/2 in airways, NOX1/DUOX2 in GIT) that participate in the antimicrobial response (97, 110, 148–150). Transient or stable expression of the NOX1 or DUOX2 complex in several epithelial cell lines decreased pathogen attachment and invasion without affecting bacterial viability (151, 152). NOX1 or DUOX2 mediated H2O2 release interfered with the pathogenicity of bacteria by inducing irreversible oxidative modifications in bacterial enzymes and proteins essential for maintaining virulence factor synthesis (22, 23). Duox inactivation in mice, achieved by deleting the essential partner protein Duoxa, increased gastric colonization with Helicobacter felis, reflecting the protective effect of H2O2 in host defense (153). Infection of these mice with Salmonella Typhimurium augmented systemic dissemination of the pathogen, suggesting that Duox is an integral component of the protective mucosal barrier in the small intestine (19). In murine airways Duox silencing increased the Influenza A virus (IAV) load by interfering with viral replication, at least in part by affecting the nuclear splicing machinery and assembly of virions (111). Recent studies in DUOX2 knockout primary human nasal epithelial cells and in Duox2 inactivated mutant mice linked this oxidase isoform further to IAV host defense (154). Nox1 has also been connected to host protection in IAV infection as Nox1 deficiency resulted in increased chemokine and proinflammatory cytokine generation, and extensive 3-nitrotyrosine modification of murine lung tissue (155). In IAV infected mouse macrophages Nox2-derived endosomal ROS caused suppression of TLR7-dependent antiviral cytokines, suggesting distinct roles of phagocyte Nox2 (i.e. detrimental) in contrast to a beneficial role of Nox1 during IAV infection (156).
Pathogen recognition by epithelial cells induces chemokine production, leading to the recruitment of neutrophils and macrophages to the site of injury. Innate immune cells engage in proteolytic and oxidative killing of pathogens, mainly mediated by secondary reactive species such as hypochlorous acid and peroxynitrite that rely on NOX2, mitochondria, myeloperoxidase and iNOS (157–159). Superoxide generated by NOX2 is essential for host protection against pathogens, as mutational inactivation of NOX2 complex subunits, a characteristic feature of CGD patients, profoundly impedes the ability to clear certain bacterial and fungal infections (160). Studies using murine CGD hosts have advanced our understanding of the mechanisms associated with host protection by Nox2 that seem to depend on the pathogen and the microenvironment encountered. For instance, intestinal colonization by Salmonella Typhimurium was increased in streptomycin pretreated Nox2 deficient mice (i.e., Cybb<sup>−/−</sup>) (161). Conversely, these mice were not more susceptible to infection with themurine pathogen Citrobacter rodentium (120). Superoxide produced by Nox2 played only a minor role in protection against Mycobacterium tuberculosis (MtB) infection in contrast to reactive nitrogen species (RNS)-associated immunity, which seems preponderant in the control of murine lung infection with Mtb (162–165). Evasion of ROS-mediated killing (mROS and Nox2) was recently associated with Mtb virulence factor secretion and macrophage fatty acid catabolism, thereby improving mycobacterial survival in macrophages (166, 167).

These observations support the idea of a complex interaction between antimicrobial ROS, environmental factors, and virulence mechanisms employed by pathogens (e.g., detoxification enzymes), all impacting infection outcome and host protection (168). Redox-dependent mechanisms triggered by pathogen recognition in innate immune cells include the pathogen itself (e.g., size, type), and driving superoxide production in the appropriate subcellular compartment (e.g., phagosome, endosome, extracellular environment) by a specific source (e.g., NOX2, mitochondria) (169, 170). Upon pathogen uptake the phagosome is the main compartment where primary and secondary ROS accumulate in high concentrations. Assembly and activation of NOX2 at the phagosome membrane triggers the so-called ‘phagocyte oxidative burst’ that together with proteases supports killing of bacterial and fungal pathogens. In addition to phagosomal NOX2 activity, bactericidal ROS generation in the phagosome is maximized by mitochondria, with both ROS sources cooperating in pathogen killing (171). Mitochondria are recruited to the phagosome of infected macrophages, where they deliver mitochondria-derived effector molecules, including mROS in mitochondria-derived vesicles, to support intraphagosomal killing of pathogens (68, 172–174). Mitochondria mobility to the phagosome is promoted by the protein kinases Mst1/2. Upon phagocytosis, TLR-mediated signaling activates Mst1/2, triggering a TRAF6-Rac signaling axis involved in cytoskeletal rearrangements (172). The NOX2 complex localizes also to the plasma membrane, where it releases superoxide into the extracellular space in response to microbial patterns or large microorganisms that cannot be classically engulfed by phagocytic cells.

Neutrophils employ as additional host defense mechanism the release of nuclear chromatin, forming neutrophil extracellular traps (NETs). NETs act as defense mechanism against pathogens via entrapment and antimicrobial activity (175, 176). The sequence of events for NET formation is not completely defined (177), but it appears that NET release can be triggered in a ROS dependent or independent manner according to the pathogen or stimulus encountered (178–180). Neutrophils derived from CGD patients show an impairment in NET formation and ineffective control of Aspergillus species in the airways, leading to invasive aspergillosis. The importance of a functional NOX2 complex in restricting A. nidulans conidia and hyphae by NET formation was confirmed in a CGD patient undergoing gene therapy (181). The real-life situation of the severely compromised host immunity in CGD emphasizes the importance of ROS in host defense and serves as a reminder that certain disorders or disturbed mucosal environments may greatly benefit from improving oxidant production.

**IMPROVING ROS LEVELS AS THERAPEUTIC INTERVENTION**

In pathological conditions ROS have been linked to ‘oxidative stress’ when observing oxidatively modified proteins, lipids and DNA, yet without definite identification of the ROS generating enzyme(s) involved or how the damaging sequence of events was initiated. Moreover, several disease-causing genetic variants and disease-associated genetic risk factors have shed light on the harmful consequences of insufficient ROS production for H2O2-induced oxidative modifications, redox signaling and host defense (e.g., CGD, hypothyroidism, inflammatory bowel disease) (33). To date most strategies targeting oxidative stress (i.e., antioxidant therapy) are based on the delivery of ROS scavengers, ROS converting or degrading compounds or on non-selective enzyme inhibitors to protect tissues and organs, but clinical results of antioxidant treatments in inflammatory diseases have so far been disappointing (182–184). More recently, treatments aimed at generating excessive concentrations of ROS or at inhibiting cellular antioxidant defense systems at a designated target location (i.e., prooxidant therapy) have been developed to promote cancer cell death or antimicrobial killing through oxidative damage (185, 186). In contrast, ROS/redox-modulating therapies take a different, nontraditional approach. The goal of this strategy is a middle path intended to restore physiological levels of primary ROS (superoxide, H2O2) or, in certain circumstances, to moderately augment beneficial oxidants. This approach will require innovations in pharmaceutical drug technology such as nanotechnology and smart materials (e.g., liposomes, hydrogels, nanocarriers) enabling controlled delivery of therapeutic agents (e.g., ROS producing or converting systems) to a target site due to utilization of stimulus-sensitive materials (187–190). In some
settings ROS deficiencies may be partially compensated by pharmacological manipulation of endogenous oxidant producing enzymes. While still in their infancy science-based fine-tuning and balancing oxidant therapies are poised to deliver prophylactic and remedial benefits, namely improving homeostasis and host defense. This is particularly relevant for primary ROS with their essential role in redox signaling and dedicated immune functions. Here we summarize concepts for restoring physiological levels of beneficial oxygen-derived species in terms of technological approaches and therapeutic applications (Figure 1).

**Established and Emerging Strategies for Oxidant Generation**

**Use of Hydrogen Peroxide**

In the past, external application of H$_2$O$_2$ has been used for medicinal purposes (191, 192). Although high concentrations of H$_2$O$_2$ have well-known antiseptic properties, tissue damage may occur. On the other hand, application of lower concentrations of H$_2$O$_2$ (0.15-1.25 µmoles/wound) improved the rate of wound closure in wildtype mice and in mice deficient in Nox2-derived superoxide, thereby accelerating tissue regeneration (193, 194). Topical application of micromolar H$_2$O$_2$ promoted the phosphorylation of tyrosine residues in FAK that supported an angiogenic response via vascular endothelial growth factor (VEGF) signaling. Removal of H$_2$O$_2$ by addition of the H$_2$O$_2$ degrading enzyme catalase delayed wound healing and impeded angiogenesis (193). While these experiments may suggest direct exposure of skin to H$_2$O$_2$ as wound healing treatment, the therapeutic window is too narrow for safe and efficient tissue restitution. Further, internal administration of H$_2$O$_2$ solutions poses serious health risks and should not be promoted. To achieve a health benefit, technologies permitting modified release of a standardized dose of nanomolar H$_2$O$_2$ to specific target areas will be required. Strategies promoting controlled H$_2$O$_2$ delivery may include the utilization of nano systems, diffusible molecules, and stimulus-sensitive compounds (195–198). Stimulus-responsive materials are particularly attractive to target specific disease-associated microenvironments such as changes in pH due to inflammation (189, 199, 200). In accord, one can imagine the development of redox-sensitive materials actively releasing appropriate oxidants until a certain threshold is
achieved and the system self-inactivates. Moreover, the vehicle strategy is important. For instance, hydrogels are commonly used as drug carriers for clinical use, owing to their tunable mechanistic and physicochemical properties (201). Controlled and continuous release of H$_2$O$_2$ was achieved with an in situ forming hydrogel that can be used as antimicrobial wound dressing (202).

**Lactobacillus as H$_2$O$_2$ Source**

Lactobacilli, widely used probiotic bacteria that belong to the gastrointestinal and vaginal microbiota (203), are the microbial prototype for controlled release of nanomolar H$_2$O$_2$. Many Lactobacillus strains utilize oxygen to generate H$_2$O$_2$ by various enzymes including flavin reductase (nfr), NADH oxidase (nox) or pyruvate oxidase (pox) (204–207). Lactobacilli colonizing the mucus layer are close enough to the oxygen gradient emanating from host epithelial barrier cells (up to 3% colonizing the mucus layer are close enough to the oxygen gradient to secrete nanomolar H$_2$O$_2$ continually (208–210). A recent report linked Lactobacillus generated H$_2$O$_2$ to increased colonization resistance, protecting the host from C. rodentium infection (120). A decline in host-derived H$_2$O$_2$ due to genetic deletion or loss-of-function mutations in NADPH oxidases gives rise to microbiota dysbiosis, which is likely niche-driven and tied to changes in the intestinal microenvironment. Thus, manipulation of the microbiota with lactobacilli constitutes a potential strategy to promote microbiota diversity for improved colonization resistance. This approach can be extended to the airways colonized by their unique microbiota. Intranasal administration of probiotics (including various Lactobacillus strains) was recently proposed to modulate local immunity and epithelial barrier function (211, 212). In addition to living lactobacilli, administration of prebiotics to selectively stimulate the growth or activity of resident lactobacilli may improve the barrier redox environment and stimulate host immunity. For example, abundance of lactobacilli seems to increase following the consumption of galacto-oligosaccharides, a common prebiotic generated from the decomposition of lactose, with reported beneficial effects on immune function (203, 213).

Early findings that H$_2$O$_2$ promotes cell migration match with the positive effects of lactobacilli on wound healing. Lactobacilli secrete not only H$_2$O$_2$ but numerous other compounds such as lactic acid and bacteriocins that improve the wound environment. Nevertheless, the ability of L. johnsonii to generate H$_2$O$_2$ was directly linked to accelerated recovery and tissue restitution in murine colitis (210). Transformation of lactobacilli to express exogenous proteins can further improve their wound healing capacity as demonstrated recently for L. reuteri secreting CXCL12 (214). Lactobacilli may also release yet undefined compounds that trigger intracellular ROS generation by host cells, for example by the oxidase Nox1, to improve mucosal repair (85, 105). Bacteria or microbial-derived products can drive expression of ROS-generating enzymes in the host, likely associated with increased H$_2$O$_2$ levels. Ileal colonization with commensal segmented filamentous bacteria (SFB) increased expression of the oxidase Duox2 (19). Intraperitoneal administration of SFB-derived flagellin was sufficient to upregulate Duox2 in the small intestine, suggesting that microbial regulation of Duox2 expression may be TLR5 dependent (215).

Most studies linking lactobacilli to antimicrobial defense, mucosal healing and microbiota modification have been conducted in mice. In clinical trials the outcome of probiotic therapy in IBD has been mixed (216–219). Possible explanations range from poor standardization and viability of bacteria to insufficient colonization due to the human intestinal environment including the mucus layer, as well as to differences between mouse and human physiology such as the presence of a Lactobacillus reservoir in the murine forestomach. Another confining factor is using living organisms, which can lead to systemic bacterial dissemination. Several reports outline the risk for Lactobacillus bacteremia and septicemia in immunocompromised patients, after surgical procedures and in colitis patients (220–223). Even in mice septicemia was observed when either the orally administered dose of L. johnsonii was increased ten-fold or L. johnsonii overproducing H$_2$O$_2$ was administered, indicating that H$_2$O$_2$ production should not exceed an optimal physiological range for health benefit (210). Current developments in the field are focused on standardization, design of consortia and recombinant probiotics, but other inventive strategies as outlined below could address some shortcomings of probiotics as H$_2$O$_2$ generators.

**Application of Recombinant Enzymes**

Recombinant enzymes involved in ROS generation or conversion can be used to modulate the oxidative microenvironment. The enzyme superoxide dismutase (SOD) catalyzes the dismutation of superoxide into oxygen and H$_2$O$_2$. Several isoforms of this enzyme are expressed in both mammalian and bacterial hosts, where they serve as part of the protective antioxidant system. SOD-mediated superoxide conversion limits the generation of secondary, highly reactive oxygen and nitrogen metabolites (e.g., hydroxyl radical, peroxynitrate) that can cause irreversible modification of proteins, lipids or DNA (224, 225). Therefore, SOD-based applications have been mainly used as antioxidant strategy aiming to decrease secondary ROS levels for prevention of inflammatory diseases. A more universal utilization of SOD as physiological H$_2$O$_2$ source at mucosal surfaces is compromised by its mode of action, including reliance on inflamed conditions, in conjunction with unattainable dosing standardization, and poor enzymatic stability (226).

Many oxidoreductases generate H$_2$O$_2$ as a byproduct of their intended enzymatic reaction including carbohydrate oxidases [e.g., glucose oxidase, galactose oxidase and many others (227)], cholesterol oxidase (228), alcohol oxidase (229) and D-amino acid oxidase (230). We will discuss here as example glucose oxidase (GOx), a prominent representative of carbohydrate oxidases that catalyzes the oxidation of β-D-glucose to D-glucono-1,5-lactone with further hydrolysis to gluconic acid. GOx contains the flavin adenine dinucleotide (FAD) cofactor as initial electron acceptor, which undergoes reduction to FADH$_2$, followed by FADH$_2$ oxidation by molecular oxygen, and reduction of oxygen to H$_2$O$_2$ (231). GOx is found...
resulted in genetically engineered GOx modifications in combination with encapsulation strategies for improved long-term enzymatic activity (234). Dermatological applications of GOx as tunable H2O2 generator may hold some promise for therapy. Incorporation of GOx in a collagen dressing improved wound healing and tissue regeneration of rodent skin, presumably due to sustained release of H2O2, although oxidant measurements were not provided. This GOx treatment induced an antioxidant response by the host tissue with upregulation of SOD and catalase (235). GOx is naturally present in honey at low concentrations where it has been studied for its dual function, namely for aiding wound healing and as antimicrobial agent. A medicinal honey (surgihoneyRO™) with enhanced antimicrobial activity is on the market as a wound antiseptic dressing (236, 237). Due to its GRAS (generally recognized as safe) FDA status GOx is used by the food industry as stabilizing and antibacterial agent (238).

The GRAS status supports considering GOx for internal applications such as hydrogels or oral administration of the enzyme. A gelatin hydrogel incorporating glucose and varying GOx concentrations released micromolar H2O2 for 24-48 hours in a controlled manner and improved the proliferation of cultured endothelial cells. This effect was accompanied by a transient increase of intracellular ROS (measured as DCFH-Da signal) as well as enhanced neovascularization in a CAM model, indicating modulation of redox signaling by GOx-generated H2O2 (239, 240). For oral administration, the protection of GOx’s enzymatic activity can be achieved by microencapsulation. Diet delivered glucose might be sufficient for GOx-mediated H2O2 generation in the small intestine, while supplementation of the GOx drug carrier with compartmentalized glucose will be necessary for affecting the large intestine. Targeted, controlled delivery of GOx/glucose presents a promising opportunity to modulate intestinal redox signaling, mucosal healing and immune defense while limiting oxidative damage. Therapeutic applications of GOx/glucose or similar H2O2 generators will partially mimic the current use of lactobacilli, albeit with superior standardization, more limited dependence on the barrier microenvironment and superior safety in vulnerable patient populations. An additional benefit of the GOx/glucose reaction is the generation of the prebiotic gluconic acid as a secondary reaction product, which stimulates butyrate production in the intestine (241). Examples for potential treatment modalities are gut health improvements (e.g., barrier reinforcement, microbiota diversity), accelerated tissue restitution after injury in patients with intestinal inflammatory diseases, or prophylactic long-term modification of the intestinal environment in patients with insufficient H2O2 generation. Prime examples for the last point are certain patient populations in the categories very early onset IBD (VEO-IBD), CGD-IBD or IBD linked to variants upstream of ROS-generating enzymes (21, 242–244). Variants in genes encoding components of NOX enzymes including NOX1, NOX2 and DUOX2 confer susceptibility to VEO-IBD (152, 245–248), while NOX2 complex variants associated with CGD due to absent or minimal output of superoxide manifest in 40-50% of CGD patients as CGD-associated IBD. Functional evaluation of NOX1 and DUOX2 patient variants in model systems revealed decreased ROS production and impaired antimicrobial defense (152, 246, 247). The compromised immune defense of these hosts in combination with the ensuing dysbiotic microbiota affects not only the overall colonization resistance but also more specialized immune defense mechanisms. Diffusion of nanomolar H2O2 into extracellular pathogens is not bactericidal but can downregulate virulence factors. Nanomolar H2O2 blocked bacterial phosphotyrosine signaling required for virulence factor synthesis by irreversibly modifying tyrosine phosphorylated enzymes and proteins (22, 23). In addition, nanomolar H2O2 inhibited LEE pathogenicity island regulation in enteropathogenic bacteria (C. rodentium) due to impaired expression of the major transcriptional regulator ler, which was associated with lower pathogen colonization and improved recovery of mice (120). While the precise molecular mechanism of LEE downregulation has not yet been resolved, these studies hold great promise for H2O2-mediated interference in enteric bacterial infections. Supplying nanomolar levels of H2O2 via GOx/glucose or similar means may provide multiple benefits including host protection, reinforcement of the intestinal barrier and mucosal healing.

**Stimulation of Endogenous ROS Sources**

Instead of providing ROS by an exogenous source, agonists or drugs that stimulate expression and/or activation of a ROS-generating enzyme or alter mitochondrial function can be used to improve immune responses. Currently this area is dominated by improving innate immune cell-derived superoxide, but one can envision that future applications will be directed at epithelial superoxide/H2O2-producing enzymes. Neutrophils and macrophages are crucial for pathogen defense with NOX2-derived superoxide playing a key role in this process. Enhancing the neutrophil activation status, and in particular the oxidative burst, will not only be desirable in infections but also in inflammatory disorders (249–251). Activating NOX2 can be achieved by targeting upstream pathways. One approach focusses on developing formyl peptide receptor (FPR1, FPR2) agonists selectively binding to a receptor conformation that will favor one signaling output over another (i.e. biased signaling) without accelerating receptor desensitization (249). In neutrophils FPRs regulate directional migration, secretion of inflammatory mediators and superoxide generation by NOX2. While FPRs are usually triggered by microbial derived formylated peptides, endogenous proteins or lipopeptides, small compounds and peptides acting as exogenous FPR agonists have been identified. Examples are the FPR1 agonist RE-04-001, FPR2 agonists BMS-986235 and Act-3899499, and dual FPR1/2 agonists such as compound 17b (252–255).
Biased FPR agonists causing functional selectivity in neutrophil responses, namely either inducing chemotaxis or superoxide production, can be used as NOX2 activators (252, 256). Nox2 activity has been associated with the resolution of inflammation in colitis (133), and the pro-resolving Fpr2 agonist Annexin-A1 accelerated wound healing of the murine colonic epithelium via the oxidase Nox1 (81).

Another approach is using the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) to augment NOX2 derived superoxide production by acting as priming agent in neutrophils while elevating the phagosomal pH in macrophages (257–259). The efficacy of GM-CSF administration as immunostimulatory adjuvant has been evaluated in clinical trials. In a randomized trial involving critically ill patients, subcutaneous injections with GM-CSF increased neutrophil phagocytic capacity but did not improve superoxide production (EudraCT 2011-005815-10), while an earlier trial using intravenous delivery of GM-CSF had reported statistically significant enhancement of neutrophil superoxide generation (260). GM-CSF has also been assessed in the context of CGD patients. While reconstitution of the oxidative burst in isolated neutrophils was not achieved, as expected for a disease caused by genetic mutations, GM-CSF has shown some promise in treating CGD-IBD by undefined mechanism(s) (261–263). In non-CGD patients biased targeting of NOX2 activating pathways may hold promise, and analogous strategies should be feasible for development of activators of other NOX/DUOX enzymes or of other ROS sources.

Generation of Compensatory ROS
Therapeutically enhancing ROS production in CGD or VEO-IBD patients is imperative for antimicrobial defense, for resolution of inflammation and for repair processes. In these patients gene editing, administration of exogenous ROS generators or stimulation of other endogenous ROS sources are the only options to improve their ROS status. Kuhns and coworkers showed that modest residual superoxide production is sufficient to prevent life-threatening infections in CGD patients (264). Partial restoration of macrophage and dendritic cell superoxide in functional Ncf1 rescue mice was adequate to dampen hyperinflammation (265). These considerations are the basis for screening and identifying compounds capable of compensating partially for NOX2 enzyme activity.

The first compound in this class is the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone, a drug approved for Type 2 diabetes. As proof of concept, pioglitazone treatment of cultured CGD patient-derived monocytes or of Nox2 deficient mice increased mROS production and subsequently the bactericidal capacity of immune cells (266). Pioglitazone and the related rosiglitazone induced mROS and NETs in CGD neutrophils (267). Monocytes from CGD patients and Nox2 deficient macrophages were impaired in PPARγ signaling, impacting their efferocytosis function which was restored by pioglitazone treatment (268, 269). Increased mROS generation and restoration of efferocytosis were also observed in monocytes isolated from two CGD patients after 30 days of oral pioglitazone treatment, supporting the effectiveness of pioglitazone therapy for superoxide production and improved immune cell function (269). A clinical study reported the effects of daily pioglitazone treatment in an infant with CGD. Using dihydrorhodamine (DHR) fluorescence as readout for ROS an increase in DHR positive granulocytes after 25 days of treatment was observed. The increase in the phorbol ester stimulated DHR signal was relatively low in comparison with healthy donor cells but it was maintained over several weeks, and the clinical condition of the patient progressively improved (270). Efficacy and safety of pioglitazone was assessed in a clinical trial enrolling CGD patients with severe infection. Phase 2 of the study was terminated when the DHR fluorescence signal did not improve in neutrophils after 90 days of treatment with pioglitazone (clinicaltrials.gov NCT03080480). Long-term administration of pioglitazone did not lead to drug-related adverse effects or exacerbation of infection (271). The variation in outcomes might be attributable to different pioglitazone dosage, or to the often required combination therapy with antibiotics and/or interferon IFN-γ. Further studies are necessary to determine if pioglitazone will provide a therapeutic option for CGD patients, for example as adjuvant therapy in severe bacterial infections or as prophylaxis. At this point only hematopoietic stem cell transplantation, gene therapy or gene editing with CRISPR-Cas9 offer a cure for CGD (272).

Future Directions
The field of redox medicine has blossomed over the last decade, but further progress will depend on connecting more tightly distinct oxidant species and their enzymatic sources to physiological or pathophysiological processes. Another important factor will be uncovering and manipulating specific microenvironments. The chemical milieu, in particular oxygen availability, is a limiting factor for ROS production, but the hypoxia developing due to ROS production (e.g., via the neutrophil oxidative burst) in a low oxygen environment can have beneficial effects such as resolution of inflammation and accelerated tissue restitution (133). The presence and concentration of H2O2 and secondary oxidants (hypochlorous acid, peroxynitrite) will modify the barrier environment and the interactions between host and microbiota, leading to changes in microbiota diversity, composition, and the microbial metabolome that can be beneficial or harmful for the host. Case in point is the intestinal dysbiosis and appearance of pathobions in NADPH oxidase deficient mice (94, 113). The nanomolar H2O2 released from mucosal barriers is inadequate for bactericidal activity, but its interference with the fitness and virulence of certain microorganisms supports its use as a promising alternative to antibiotics (273, 274). However, this antivirulence strategy will require the identification and targeting of specific pathogens to avoid the subversion of these oxidants for their own advantage as reported for some pathogenic bacteria (275–281).

Given the essential role of ROS for basic physiological functions, future therapeutics should include careful modulation of the redox state. Therapeutic interest today focuses on the margins of the ROS continuum, namely anti-
pro-oxidant interventions, but new approaches to modify physiological redox processes will be vital for improving health and well-being. Current limitations are the lack of targeted drugs modulating the activity of specific enzyme isomers or of drugs that can adapt their mode of action by sensing ROS levels in situ. Sophisticated delivery systems for novel small molecule- or peptide-based activators will help restoring or enhancing beneficial ROS (mainly H2O2) at a predetermined location in order to achieve a positive outcome and to prevent undesired side effects linked to toxicity. For this purpose, exploitation of natural properties of commensals or their genetic modification, discovery of agonists stimulating ROS-generating enzymes, design of functional materials and delivery vehicles releasing H2O2, for example by utilizing recombinant enzyme-substrate pairs, will provide therapeutic options for infections, inflammatory diseases, and regenerative medicine. Next generation treatments will likely include strategies for altering the chemical environment at defined locations in a sustainable manner, with ROS being one of the key targets.

**AUTHOR CONTRIBUTIONS**

Concept (UK). Writing and editing (AD, UK). Figure design (AD). Funding (UK). All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We acknowledge the support of Science Foundation Ireland (16/IA/4501) and the National Children’s Research Center (K/17/2) (both UK).

**REFERENCES**

1. Holmstrom KM, Finkel T. Cellular Mechanisms and Physiological Consequences of Redox-Dependent Signalling. *Nat Rev Mol Cell Biol* (2014) 15(6):411–21. doi: 10.1038/nrm3801
2. Sies H, Jones DP. Reactive Oxygen Species (ROS) as Pleiotropic Physiological Signalling Agents. *Nat Rev Mol Cell Biol* (2020) 21(7):363–83. doi: 10.1038/s41555-020-0230-3
3. Lambeth JD, Neish AS. Nox Enzymes and New Thinking on Reactive Oxygen: A Double-Edged Sword Revisited. *Annu Rev Pathol* (2014) 9:119–45. doi: 10.1146/annurev-pathol-012513-104651
4. Panday A, Sahoo MK, Osorio D, Batra S. NADPH Oxidas: An Overview From Structure to Innate Immunity-Associated Pathologies. *Cell Mol Immunol* (2015) 12(1):5–23. doi: 10.1038/cmi.2014.89
5. Winterbourn CC, Kettle AJ. Redox Reactions and Microbial Killing in the Neutrophil Phagosome. *Antioxid Redox Signal* (2013) 18(6):642–60. doi: 10.1089/ars.2012.4827
6. Sema LA, Chandel NS. Physiological Roles of Mitochondrial Reactive Oxygen Species. *Mol Cell* (2012) 48(2):158–67. doi: 10.1016/j.molcel.2012.09.022
7. Renierie CK, Chandel NS. ROS-Dependent Signal Transduction. *Curr Opin Cell Biol* (2015) 33:8–13. doi: 10.1016/j.cceb.2014.09.010
8. Veal EA, Day AM, Morgan BA. Hydrogen Peroxide Sensing and Signalling, *Mol Cell* (2007) 26(1):14–8. doi: 10.1016/j.molcel.2007.03.016
9. Sies H. Hydrogen Peroxide as a Central Redox Signaling Molecule in Physiological Oxidative Stress: Oxidative Eustress. *Redox Biol* (2017) 11:613–9. doi: 10.1016/j.redox.2016.12.035
10. Stocker S, Van Laer K, Mijušković A, Dick TP. The Conundrum of Hydrogen Peroxide Signaling and the Emerging Role of Peroxiredoxins as Redox Relay Hubs. *Antioxid Redox Signal* (2018) 28(7):558–73. doi: 10.1089/ars.2017.7162
11. Deshmukh P, Unni S, Krishnappa G, Padmanaban B. The Keap1-Nrf2 Pathway: Promising Therapeutic Target to Counteract ROS-Mediated Damage in Cancers and Neurodegenerative Diseases. *Biophys Rev* (2017) 9(1):41–56. doi: 10.1007/s12551-016-0244-4
12. Suzuki T, Muramatsu A, Saito R, Iso T, Shibata T, Kuvata K, et al. Molecular Mechanism of Cellular Oxidative Stress Sensing by Keap1. *Cell Rep* (2019) 28(3):746–8. doi: 10.1016/j.celrep.2019.06.047
13. Imlay JA. Transmission Factors That Defend Bacteria Against Reactive Oxygen Species. *Annu Rev Microbiol* (2013) 67:99–138. doi: 10.1146/annurev-micro-091014-104322
14. Reniere ML. Reduce, Induce, Thrive: Bacterial Redox Sensing During Pathogenesis. *J Bacteriol* (2018) 200(17). doi: 10.1128/JB.00128-18
15. Imlay JA. Where in the World do Bacteria Experience Oxidative Stress? *Environ Microbiol* (2019) 21(2):521–30. doi: 10.1111/1462-2920.14445
16. Li X, Imlay JA. Improved Measurements of Scant Hydrogen Peroxide Enable Experiments That Define Its Threshold of Toxicity for Escherichia Coli. *Free Radic Biol Med* (2018) 120:217–27. doi: 10.1016/j.freeradbiomed.2018.03.025
17. Lee C, Lee SM, Mukhopadhyay P, Kim SJ, Lee SC, Ahn WS, et al. Redox Regulation of OxyR Requires Specific Disulfide Bond Formation Involving a Rapid Kinetic Reaction Path. *Nat Struct Mol Biol* (2004) 11(12):1179–85. doi: 10.1038/nsmb856
18. Zheng M, Aslund F, Storz G. Activation of the OxyR Transcription Factor by Reversible Disulfide Bond Formation. *Science* (1998) 279(5357):1718–21. doi: 10.1126/science.279.5357.1718
19. Grasberger H, Gao J, Nagao-Kitamoto H, Kitamoto S, Zhang M, Kamada N, et al. Increased Expression of DUOX2 Is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine. *Gastroenterology* (2015) 149(7):1849–59. doi: 10.1053/j.gastro.2015.07.062
20. Jones RM, Neish AS. Redox Signaling Mediated by the Gut Microbiota. *Free Radic Biol Med* (2017) 105:41–7. doi: 10.1016/j.freeradbiomed.2016.10.495
21. Aviello G, Knaus UG. NADPH Oxidas and ROS Signaling in the Gastrointestinal Tract. *Mucosal Immunol* (2018) 11(4):1011–23. doi: 10.1038/s41385-018-0021-8
22. Corcioneirochi N, Alvarado LA, Sharp TH, Strengert M, Alemka A, Mantell J, et al. Mucosal Reactive Oxygen Species Decrease Virulence by Disrupting Campylobacter jejuni Phosphorytrosine Signaling. *Cell Host Microbe* (2012) 12(1):47–59. doi: 10.1016/j.chom.2012.05.018
23. Alvarez LA, Kovacic L, Rodriguez J, Gosemann JH, Kubicz M, Piricalabioru GG, et al. NADPH Oxidase-Derived H2O2 Subverts Pathogen Signaling by Oxidative Phosphotyrosine Conversion to PB-DOPA. *Proc Natl Acad Sci USA* (2016) 113(37):10406–11. doi: 10.1073/pnas.1605443113
24. Belambri SA, Rolas I, Raad H, Hurtado-Nedelee M, Dang PM, El-Benna J. NADPH Oxidase Activation in Neutrophils: Role of the Phosphorylation of its Subunits. *Eur J Clin Invest* (2018) 48(Suppl 2):e12951. doi: 10.1111/eci.12951
25. Rovira-Llopin S, Banuls I, Diaz-Morales N, Hernandez-Mijares A, Rocha M, Victor VM. Mitochondrial Dynamics in Type 2 Diabetes: Pathophysiological Implications. *Redox Biol* (2017) 11:637–45. doi: 10.1016/j.redox.2017.01.013
26. Teleanu RI, Chircov C, Grumezescu AM, Volceanov A, Teleanu DM. Antioxidant Therapies for Neuroprotection-A Review. *J Clin Med* (2019) 8(10):1659. doi: 10.3390/jcm8101659
27. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-Analysis. *JAMA* (2007) 297(8):842–57. doi: 10.1001/jama.297.8.842
28. Schmidt HH, Stocker R, Vollbracht C, Paulsen G, Riley D, Daiber A, et al. Antioxidants in Translational Medicine. *Antioxid Redox Signal* (2015) 23(14):1130–43. doi: 10.1089/ars.2015.6393
29. Szuklidouks MA, von Frankenben AD, Uetshneider KM. The Antioxidant N-Acetylcyesteine Does Not Improve Glucose Tolerance or Beta-Cell Function in Type 2 Diabetes. J Diabetes Complications (2013) 30(6):618–22. doi: 10.1016/j.jdiacomp.2016.02.003

30. Krysko RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, et al. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium Trial (Preadvise). JAMA Neurol (2017) 74(5):567–73. doi: 10.1001/jamanetworkneurol.2016.5778

31. Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral Adjunct Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients (2018) 10(11):1737. doi: 10.3390/nu10111737

32. Shaito A, Posadino AM, Younes N, Hasen H, Halabi S, Alhababi D, et al. Potential Adverse Effects of Resveratrol: A Literature Review. Int J Mol Sci (2020) 21(6):2084. doi: 10.3390/ijms21062084

33. O’Neill S, Brautl J, Stasia MJ, Knaus UG. Genetic Disorders Coupled to ROS Deficiency. Redox Biol (2015) 3:635–56. doi: 10.1016/j.redox.2015.07.009

34. Schieber M, Chandel NS. ROS Function in Redox Signaling and Oxidative Stress. Curr Biol (2014) 24(10):R453–62. doi: 10.1016/j.cub.2014.03.034

35. Forman HJ, Ursini F, Maiorino M. An Overview of Mechanisms of Redox Signaling. J Mol Cell Cardiol (2014) 73:2–9. doi: 10.1016/j.yjmcc.2014.01.018

36. Radi R. Oxygen Radicals, Nitric Oxide, and Peroxynitrite: Redox Pathways in Molecular Medicine. Proc Natl Acad Sci USA (2018) 115(25):5389–48. doi: 10.1073/pnas.1804932115

37. Jennings RT, Singh AK, Knaus UG. Redox Regulator Network in Inflammation. Curr Opin Physiol (2019) 9:9–17. doi: 10.1016/j.jcophys.2019.03.002

38. Albadri S, Naso F, Thauvin M, Gauron C, Parolin C, Duroure K, et al. Redox-Active Site of Thioredoxin Is Directly Involved in Apoptosis Signal-Activating Domain Interaction of NADPH Oxidase-Deficient Patients to Lipopolysaccharide and Serum Amyloid A. Immunol Lett (2004) 94(1-2):43–6. doi: 10.1016/j.imlet.2004.04.016

39. Brown KL, Bylund J, MacDonald KL, Song-Zhao GX, Elliott MR, Falsafi R, et al. ROS-Deficient Monocytes Have Aberrant Gene Expression That Correlates With Inflammatory Disorders of Chronic Granulomatous Disease. In: Immunol (2018) 129:9–102. doi: 10.1016/j.clim.2008.06.005

40. McElhice S, Volpp BD, Dinauer MC, Blum JS. Hyper-Responsive Toll-like Receptor 7 and 9 Activation in NADPH Oxidase-Deficient B Lymphoblasts. Immunol (2015) 146(4):595–606. doi: 10.1011/imm.12530

41. Meda Scoppomela V, Valencia RG, Pastukhov O, Duppenthaler A, Dettmer MS, Erb J, et al. High Levels of IL-18 and IFN-γ GammaChronic Inflamed Tissue in Chronic Granulomatous Disease. Front Immunol (2019) 10:2236. doi: 10.3389/fimmu.2019.02236

42. Meissner F, Seger RA, Moshou D, Fischer A, Reichenbach J, Zychlinsky A. Inflammomsome Activation in NADPH Oxidase Defective Mononuclear Phagocytes From Patients With Chronic Granulomatous Disease. Blood (2010) 116(9):1570–3. doi: 10.1182/blood-2010-01-264218

43. de Luca A, Smeeckens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, et al. IL-1 Receptor Blockade Restores Autophagy and Reduces Inflammation in Chronic Granulomatous Disease in Mice and in Humans. Proc Natl Acad Sci USA (2014) 111(9):3526–31. doi: 10.1073/pnas.1322831111

44. Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, Feminilla J, et al. NADPH Oxidase Inhibits Immune Responses in the Lungs in Mice. PloS One (2010) 5(3):e9631. doi: 10.1371/journal.pone.0009631

45. Song Z, Huang G, Obrien MC, Grimes D, Gu J, Luke CJ, et al. NADPH Oxidase Controls Pulmonary Neutrophil Infiltration in the Response to Fungal Cell Walls by Limiting LTβR. Blood (2020) 135(20):2179–88. doi: 10.1182/blood.2019003525

46. Dinauer MC. Inflammatory Consequences of Inherited Disorders Affecting Neutrophil Function. Blood (2019) 133(20):2130–9. doi: 10.1182/blood-2018-11-44563

47. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current Concepts of Hyperinflammation in Chronic Granulomatous Disease. Clin Dev Immunol (2012) 2012:252460. doi: 10.1155/2012/252460

48. Kuijpers T, Lutter R. Inflammation and Repetitive Infections in CGD: Two Sides of a Coin. Cell Mol Life Sci (2012) 69:675–15. doi: 10.1007/s00018-011-0834-z

49. Cachat J, Defert C, Alessandrin M, Roux-Lambard P, Le Guellec A, Stasia MJ, et al. Altered Humoral Immune Responses and IgG Subtypes in NOX2-Deficient Mice and Patients: A Key Role for NOX2 in Antigen-Presenting Cells. Front Immunol (2018) 9:1555. doi: 10.3389/fimmu.2018.01555

50. Weinberg SE, Sena LA, Chandel NS. Mitochondria in the Regulation of Innate and Adaptive Immunity. Immunity (2015) 42(3):406–17. doi: 10.1016/j.immuni.2015.02.002

51. Mehta MM, Weinberg SE, Chandel NS. Mitochondrial Control of Inflammation: Beyond ATP. Nat Rev Immunol (2017) 17(10):680–20. doi: 10.1038/nri.2017.66

52. Chandel NS, Schumacker PT, Arch RH. Reactive Oxygen Species Are Downstream Products of TRAF-Mediated Signal Transduction. J Biol Chem (2001) 276(46):42728–36. doi: 10.1074/jbc.M103074200

53. West AP, Brodsky IE, Rahner C, Wook DK, Erdjument-Bromage H, Tempst P, et al. TLR Signalling Augments Macrophage Bactericidal Activity

Frontiers in Immunology | www.frontiersin.org 13 June 2021 | Volume 12 | Article 698042
Through Mitochondrial ROS. *Nature* (2011) 472(7344):476–80. doi: 10.1038/nature09973.

Herb M, Gluschankiewicz F, Wegmann K, Farid A, Wolf A, Uerdmehlen O, et al. Mitochondrial Reactive Oxygen Species Enable Proinflammatory Signaling Through Disulphide Linkage of NEMO. *Sci Signal* (2019) 12(568). doi: 10.1126/scisignal.aar5926.

Zhou R, Yazdi AS, Menu P, Tschopp J. A Role for Mitochondria in NLRP3 Inflammasome Activation. *Nature* (2011) 469(7329):221–5. doi: 10.1038/nature09663.

Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC, Salter RD. Mitochondrial Reactive Oxygen Species Induces NLRP3-Dependent Lysosomal Damage and Inflammasome Activation. *J Immunol* (2013) 191(10):5230–8. doi: 10.4049/jimmunol.1301490.

Yang Y, Wang H, Kosadir M, Song H, Shi F. Recent Advances in the Mechanisms of NLRP3 Inflammasome Activation and Its Inhibitors. *Cell Death Dis* (2019) 10(2):128. doi: 10.1038/s41419-019-1413-8.

Ives A, Nomura J, Martinon F, Roger T, LeRoy D, Miner JN, et al. Xanthine Oxidoreductase Regulates Macrophage IL1beta Secretion Upon NLRP3 Inflammasome Activation. *Nat Commun* (2015) 6:6555. doi: 10.1038/ncomms7555.

van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, Ives A, Nomura J, Martinon F, Roger T, LeRoy D, Miner JN, et al. Xanthine Oxidoreductase Regulates Macrophage IL1beta Secretion Upon NLRP3 Inflammasome Activation. *Nat Commun* (2015) 6:6555. doi: 10.1038/ncomms7555.

van der Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, Ives A, Nomura J, Martinon F, Roger T, LeRoy D, Miner JN, et al. Xanthine Oxidoreductase Regulates Macrophage IL1beta Secretion Upon NLRP3 Inflammasome Activation. *Nat Commun* (2015) 6:6555. doi: 10.1038/ncomms7555.
mediated Generation of Reactive Oxygen Species. EMBO J (2013) 32 (23):3017–28. doi: 10.1038/embj.2013.224

106. Sokol H, Backhed F. The Gut Microbiota Engages Different Signaling Pathways to Induce Duox2 Expression in the Ileum and Colon Epithelium. Mucosal Immunol (2015) 8(2):372–9. doi: 10.1038/mi.2014.74

107. Yardeni T, Tanes CE, Bittinger K, Mattei LM, Schafer PM, Singh LN, et al. Host Mitochondria Influence Gut Microbiome Diversity: A Role for ROS. Sci Signal (2012) 5(2):388. doi: 10.1126/scisignal.3aw3159

108.聿matizoioudou C, Rocha SDC, Haebeth OA, Rudi K, Carlsen H, Kielland A. iNOS- and NOX1-Dependent ROS Production Maintains Bacterial Homeostasis in the Ileum of Mice. Mucosal Immunol (2018) 11(3):774–84. doi: 10.1038/mi.2017.106

109. Liu J, Iwata K, Zhu K, Matsumoto M, Matsumoto K, Asaoka N, et al. NOX1-/iNOS- and NOX1-dependent ROS Production Maintains Bacterial Homeostasis in the Ileum of Mice. Mucosal Immunol (2018) 11(3):774–84. doi: 10.1038/mi.2017.106

110. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. Intestinal Dysbiosis in Inflammatory Bowel Disease Associated With Primary Immunodeficiency. J Allergy Clin Immunol (2019) 143(2):775–778 e6. doi: 10.1016/j.jaci.2018.09.021

111. Falcone EL, Corvilain B, Dumont JE, Miot F. Roles of DUOX-mediated Hydrogen Peroxide in Metabolism, Host Defense, and Signaling. Antioxid Redox Signal (2014) 20(17):2776–93. doi: 10.1089/ars.2013.5602

112. Sokol H, Mahlaoui N, Aguilar C, Bach P, Join-Lambert O, Garraffo A, et al. NOX2-dependent Regulation of Inflammatory Macrophages as an Anti-Inflammation Mechanism. Am J Physiol Cell Physiol (2019) 316(1):C205–17. doi: 10.1152/ajpcell.00346.2016

113. Liang D, Alife R, Zhao Q, Asmis R. NOX4 is a Novel Inducible Sensor of Reactive Oxygen Species in Monocytes and Macrophages and Mediates Oxidized Low Density Lipoprotein-Induced Macrophage Death. Circ Res (2010) 106(9):1489–97. doi: 10.1161/CIRCRESAHA.109.215392

114. He C, Larson-Casey JL, Davis D, Hanumanthu VS, Longhini ALF, Thannickal VJ, et al. NOX4 Modulates Macrophage Phenotype and Macrophage Biogenesis in Asbestosis. JCI Insight (2019) 4(16). doi: 10.1172/jci.insight.126551

115. Kim YM, Kim SJ, Tatsunami R, Yamamura H, Fukai T, Ushio-Fuku M. ROS-Induced ROS Release Orchestrate by Nox4, Nox2, and Mitochondria in VEGF Signaling and Angiogenesis. Am J Physiol Cell Physiol (2017) 312 (6):C749–64. doi: 10.1152/ajpcell.00034.2016

116. Mori K, Uchida T, Yoshiie T, Mizote F, Ishikawa F, Katsuyama M, et al. A Mitochondrial ROS Pathway Controls Matrix Metalloproteinase 9 Levels and Invasive Properties in RAS-activated Cancer Cells. FEBS J (2019) 286 (2):345–58. doi: 10.1111/febs.15251

117. Fukai T, Ushio-Fukai M. Cross-Talk Between NADPH Oxidase and Mitochondria: Role in ROS Signaling and Angiogenesis. Cells (2020) 9 (8):1849. doi: 10.3390/cells9081849

118. Mills EL, O’Neill LA. Reprogramming Mitochondrial Metabolism in Macrophages as an Anti-Inflammatory Signal. Eur J Immunol (2016) 46 (1):13–21. doi: 10.1002/eji.201445427

119. Peiseler M, Kubes P. More Friend Than Foe: The Emerging Role of NADPH Oxidases in Bone Marrow-Derived Cells Modulates Intestinal Barrier Function. J Cell Host Microbe (2016) 20(3):3017. doi: 10.1038/jcchm.2016.04.007

120. Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, Bowers BE, et al. Transmigrating Neutrophils Shape the Mucosal Microenvironment Through Localized Oxygen Depletion to Influence Resolution of Inflammation. Immunity (2014) 40(1):66–77. doi: 10.1016/j.immuni.2013.11.020

121. Peiseler M, Kubes P. More Friend Than Foe: The Emerging Role of NADPH Oxidases in Bone Marrow-Derived Cells Modulating Intestinal Barrier Function. J Cell Host Microbe (2016) 20(3):3017. doi: 10.1038/jcchm.2016.04.007

122. Herp S, Brugiroz S, Garzetti D, Ring D, Jochum LM, Beutler M, et al. Macrophage NADPH Oxidase Modulates Regulatory T Cell Function through ROS: Identification of Inflammatory Macrophage Subtypes. J Immunol (2019) 202(3):1018. doi: 10.1016/j.jimmunol.2019.03.004

123. Ricciardou C, Rocha SDC, Haebeth OA, Rudi K, Carlsen H, Kielland A. iNOS- and NOX1-Dependent ROS Production Maintains Bacterial Homeostasis in the Ileum of Mice. Mucosal Immunol (2017) 11(3):774–84. doi: 10.1038/mi.2017.106

124. Caruso R, Mathes T, Martens EC, Kamada N, Nusrat A, Inohara N, et al. Host Mitochondria Influence Gut Microbiome Diversity: A Role for ROS. Sci Signal (2012) 5(2):388. doi: 10.1126/scisignal.3aw3159

125. Barrett JP, Henry RJ, Villapol S, Stoica RA, Kumar A, Burns MP, et al. NOX2 Deficiency Alters Macrophage Phenotype Through an IL-10/STAT3 Dpendent Mechanism: Implications for Traumatic Brain Injury. J Neuroinflamm (2015) 12:165. doi: 10.1186/s12974-017-0843-4

126. Xu Q, Choksi S, Qu J, Jiang C, Choe M, Banfi B, et al. NADPH Oxidases Are Essential for Macrophage Differentiation. J Biol Chem (2016) 291(38):20030–41. doi: 10.1074/jbc.M116.731216

127. Maiau R, Singh N, Gan L, Ringwood L, Li L. IRAK-1 Contributes to Lipopolysaccharide-Induced Reactive Oxygen Species Generation in Macrophages by Inducing NOX1-mRNA and Rac1 Activation and Suppressing the Expression of Antioxidative Enzymes. J Biol Chem (2009) 284(5):35403–11. doi: 10.1074/jbc.M109.059501

128. He C, Larson-Casey JL, Davis D, Hanumanthu VS, Longhini ALF, Thannickal VJ, et al. NOX4 Modulates Macrophage Phenotype and Macrophage Biogenesis in Asbestosis. JCI Insight (2019) 4(16). doi: 10.1172/jci.insight.126551
181. Bianchi M, Hakim A, Brinkmann V, Sier U, Seger RA, Zychlinsky A, et al. Restoration of NET Formation by Gene Therapy in CGD Controls Aspergillosis. *Blood* (2009) 114(13):2619–22. doi: 10.1182/blood-2009-05-221606.

182. Moura DA, de Andrade KQ, dos Santos JC, Araujo OR, Goulart MO. Antioxidant Therapy for Treatment of Inflammatory Bowel Disease: Does It Work? *Redox Biol* (2015) 3:671–9. doi: 10.1016/j.redox.2015.10.006.

183. Li CW, Li LL, Chen S, Zhang JX, Lu WL. Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases. *Front Bioeng Biotechnol* (2020) 8:200. doi: 10.3389/fbioe.2020.00220.

184. Bourgonje AR, Feelisch M, Faber KN, Pasch A, Dijkstra G, van Goor H. Reactive Oxygen Species (ROS)-Based Nanomedicine. *Redox Biol* (2020) 31. doi: 10.1039/c5nr00795j.

185. Kim SJ, Kim HS, Seo YR. Understanding of ROS-Inducing Strategy in Anticancer Therapy. *Oxid Med Cell Longev* (2019) 2019:5381692. doi: 10.1155/2019/5381692.

186. Yang B, Chen Y, Shi J. Reactive Oxygen Species (ROS). Based Nanomedicine. *Chem Rev* (2019) 119(8):8811–985. doi: 10.1021/acs.chemrev.8b00626.

187. Dunnill C, Patton T, Brennan J, Barrett J, Dryden M, Cooke J, et al. Hydrogen Peroxide Production by Inflammatory Bowel Disease in the Lung Microbiota and the Gut-Lung Axis in Respiratory Infectious Diseases. *Cell Microbiol* (2019) 21(12):3217–41. doi: 10.1111/cmi.12966.

188. Roy S, Khanna S, Nallu K, Hunt TK, Sen CK. Dermal Wound Healing Is Enhanced by Hydrogen Peroxide Accumulation. *Front Immunol* (2021) 12:962217. doi: 10.3389/fimmu.2021.962217.

189. Armogida M, Nistico R, Mercuri NB. Therapeutic Potential of Targeting Hydrogen Peroxide-Forming NADH Oxidase Belonging to the Peroxiredoxin Oxidoreductase Family: Existence and Physiological Role in Bacteria. *J Bacteriol* (2001) 183(8):2431–8. doi: 10.1128/JB.183.8.2431-2438.2001.

190. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering Precision Nanoparticles for Drug Delivery. *Biomaterials* (2012) 7(11):e49215. doi: 10.1371/journal.pone.0049215.

191. Hertzberger R, Arents J, Dekker DL, Priddore RD, Gysler C, Kleerebezem M, et al. UDP-Gal Production by the Natural Gut Microbiota Is Catalytically Activated by Hydrogen Peroxide. *Acet. Appl. Microbiol* (2019) 85(6):2229–39. doi: 10.1016/j.aem.2019.04.022.

192. Nishiyama Y, Massey DM, Takeda K, Kawai T, Watanabe T, et al. Hydrogen Peroxide-Forming NADH Oxidase Required for Bacterial Growth in the Gut Microbiota. *Cell Microbiol* (2020) 22(1):128. doi: 10.1111/cmi.12086.

193. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic Review of Randomized Controlled Trials of Probiotics, Prebiotics, and Synthetic Prebiotics for the Treatment of Inflammatory Bowel Disease. *Rev Gastroenterol Hepatol* (2019) 119(8):4881–90. doi: 10.1159/000171095.

194. Albenberg L, Esipova TV, Judge CP, Bittinger K, Chen J, Laughlin A, et al. Interspecies Inhibition of Hydrogen Peroxide-Producing Pyruvate Oxidase Requires Active Pyruvate Oxidase. *Appl Environ Microbiol* (2019) 85(18). doi: 10.1128/AEM.01271-19.

195. Martens K, Pugin B, De Boeck I, Spacova I, Steelant B, Seys SF, et al. Hydrogen Peroxide-Producing Pyruvate Oxidase from Lactobacillus Delbrueckii Is Catalytically Activated by Phosphotidylethanolamine. *BMC Microbiol* (2020) 20(1):128. doi: 10.1186/s12866-020-01788-6.

196. Singh AK, Hertzberger RY, Knaus UG. Hydrogen Peroxide Production by the Lactobacillus Acidophilus Group: A Central Role for a Novel NADH-Dependent Flavin Reductase. *ACS Appl Mater Interfaces* (2020) 12:13792. doi: 10.1021/acsami.7b03870.

197. Bafeta A, Koh M, Riveros C, Ravaud P. Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota: A Systematic Review. *Ann Intern Med* (2018) 169(4):240–7. doi: 10.7326/M18-0343.

198. Jia K, Tong X, Wang R, Song X. The Clinical Effects of Probiotics for Inflammatory Bowel Disease: A Meta-Analysis. *Med (Baltimore)* (2018) 97(51):e13792. doi: 10.1097/MD.0000000000013792.

199. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic Review of Randomized Controlled Trials of Probiotics, Prebiotics, and Synthetic Prebiotics for the Treatment of Inflammatory Bowel Disease. *Frontiers in Immunology* (2019) 10:128. doi: 10.3389/fimmu.2019.00220.

200. Aswathy SH, Narendrakumar U, Manjubala I. Commercial Hydrogels for Biomedical Applications. *Heliyon* (2020) 6(4):e03719. doi: 10.1016/j.heliyon.2020.e03719.

201. Lee Y, Choi KH, Park KM, Lee JM, Park BJ, Park KD. In Situ Forming and H2O2-Responsive Hydrogels for Treatment of Drug-Resistant Bacterial Infections. *ACS Appl Mater Interfaces* (2017) 9(20):16890–9. doi: 10.1021/acsami.7b03870.
257. Weisbart RH, Kwan L, Golde DW, Gasson JC. Human GM-CSF Primes Neutrophils for Enhanced Oxidative Metabolism in Response to the Major Physiological Chemotacticant. Blood (1987) 69(1):18–21. doi: 10.1182/blood.V69.1.18.18

258. Leino L, Nuuttila J, Pelliniemi TT, Rajamaki A. Human Recombinant GM-CSF Selectively Primes Receptor Mediated Respiratory Burst of Neutrophils In Vitro. Immunol Lett (1993) 38(1):26–31. doi: 10.1016/0165-2478(93)90114-h

259. Subramanian Vignesh K, Landero Figueroa JA, Porollo A, Caruso JA, Deepe GS Jr. Granulocyte-Macrophage-Colony Stimulating Factor Induced Zn Sequestration Enhances Macrophage Superoxide and Limits Intracellular Pathogen Survival. Immunity (2013) 39(4):697–710. doi: 10.1016/j.immuni.2013.09.006

260. Presnell JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A Randomized Phase II Trial of Granulocyte-Macrophage-Colony Stimulating Factor Therapy in Severe Sepsis With Respiratory Dysfunction. Am J Respir Crit Care Med (2002) 166(2):138–43. doi: 10.1164/ajrccm.2009005

261. Muhlebach TJ, Feickert HJ, Welte K, Seger RA. Granulocyte-Macrophage Colony Stimulating Factor Does Not Improve Neutrophil Oxidative Metabolism in a Patient With Variant X-Linked Chronic Granulomatous Disease. Eur J Pediatr (1991) 150(8):575–8. doi: 10.1007/BF02072120

262. Oez S, Birkmann J, Kalden JR. Clonal Growth of Functionally Normal and Deficient Neutrophils From the Bone Marrow of a Patient With Variant Chronic Granulomatous Disease. Lack of Reconstitution of Oxidative Burst Defect by G-CSF, Gm-CSF, and IFN-gamma In Vitro. Ann Hematol (1993) 66(1):21–5. doi: 10.1007/BF01737685

263. Wang J, Mayer L, Cunningham-Rundles C. Use of GM-CSF in the Treatment of Colitis Associated With Chronic Granulomatous Disease. J Allergy Clin Immunol (2005) 115(5):1092–4. doi: 10.1016/j.jaci.2005.01.016

264. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease. N Engl J Med (2010) 363(27):2600–10. doi: 10.1056/NEJMoa1007097

265. Deffert C, Carnescacci S, Yuan H, Rougemont AL, Kelka T, Holmdahl R, et al. Hyperinflammation of Chronic Granulomatous Disease Is Abolished by NOX2 Reconstitution in Macrophages and Dendritic Cells. J Pathol (2012) 228(3):341–50. doi: 10.1002/path.4061

266. Fernandez-Boyanapalli RF, Frasch SC, Thomas SM, Malcolm KC, Nicks M, Harbeck RJ, et al. Pioglitazone Restores Phagocyte Mitochondrial Oxidants and Bactericidal Capacity in Chronic Granulomatous Disease. J Allergy Clin Immunol (2015) 135(2):517–27.e12. doi: 10.1016/j.jaci.2014.10.034

267. Hule GP, Bargir UA, Kulkarni M, Kambli P, Taur P, Desai M, et al. Does Pioglitazone Lead to Neutrophil Extracellular Traps Formation in Chronic Granulomatous Disease Patients? Front Immunol (2019) 10:1739. doi: 10.3389/fimmu.2019.01739

268. Fernandez-Boyanapalli R, Frasch SC, Riches DW, Vandivier RW, Henson PM, Bratton DL. Pargyramma Activation Normalizes Resolution of Acute Sterile Inflammation in Murine Chronic Granulomatous Disease. Blood (2010) 116(22):4512–22. doi: 10.1182/blood-2010-02-272005

269. Fernandez-Boyanapalli RF, Falcone EL, Zerbe CS, Marciano BE, Frasch SC, Henson PM, et al. Impaired Efferocytosis in Human Chronic Granulomatous Disease Is Reversed by Pioglitazone Treatment. J Allergy Clin Immunol (2015) 136(5):1399–401.e3. doi: 10.1016/j.jaci.2015.07.034

270. Migliavacca M, Assanelli A, Ferrua F, Gcalese MP, Biffi A, Frittoni M, et al. Pioglitazone as a Novel Therapeutic Approach in Chronic Granulomatous Disease. J Allergy Clin Immunol (2016) 137(6):1913–5.e2. doi: 10.1016/j.jaci.2016.01.033

271. Hu L, Liu D, Wang W, Hou J, Ying Y, Zhou Q, et al. Low-Dose Pioglitazone Does Not Increase Ros Production in Chronic Granulomatous Disease Patients With Severe Infection. J Clin Immunol (2020) 40(1):131–7. doi: 10.1007/s10875-019-0179-z

272. Gennery AR. Progress in Treating Chronic Granulomatous Disease. Br J Haematol (2021) 192(2):251–64. doi: 10.1111/bjh.16939

273. Knaus UG, Hertzberger R, Pircalabioru GG, Yousef SP, Branco Dos Santos F. Pathogen Control At The Intestinal Mucosa – H2O2 to the Rescue. Gut Microbes (2017) 8(1):67–74. doi: 10.1007/19490976.2017.1279378

274. Allen RC, Popat R, Diggle SP, Brown SP. Targeting Virulence: Can We Make Evolution-Proof Drugs? Nat Rev Microbiol (2014) 12(4):300–8. doi: 10.1038/nrmicro3232

275. Winter SE, Thienennitur P, Winter MG, Butler BP, Huseby DL, Crawford RW, et al. Gut Inflammation Provides a Respiratory Electron Acceptor for Salmonella. Nature (2010) 467(7314):426–9. doi: 10.1038/nature09415

276. Miller BM, Liou MJ, Zhang LF, Nguyen H, Litvak Y, Schorr EM, et al. Anaerobic Respiration of NOX1-Derived Hydrogen Peroxide Licenses Bacterial Growth At The Colonic Surface. Cell Host Microbe (2020) 28(6):789–797.e5. doi: 10.1016/j.chom.2020.10.009

277. Wagner PL, Acheson DW, Waldor MK. Human Neutrophils and Their Products Induce Shiga Toxin Production by Enterohemorrhagic Escherichia Coli. Infect Immun (2001) 69(3):1934–7. doi: 10.1128/IAI.69.3.1934-1937.2001

278. Los JM, Los M, Wegezyn A, Wegezyn G. Hydrogen Peroxide-Mediated Induction of the Shiga Toxin-Converting Lambdoid Prophage ST2-8624 in Escherichia Coli O157:H7. FEBS Immunol Med Microbiol (2010) 38(3):322–9. doi: 10.1111/j.1749-6632.2009.00644.x

279. Gomez SA, Abrey-Recalde MJ, Panek CA, Ferrarotti NF, Repetto MG, Mejias MP, et al. The Oxidative Stress Induced In Vivo by Shiga Toxin-2 Contributes to the Pathogenicity of Haemolytic Uraemic Syndrome. Clin Exp Immunol (2013) 173(3):463–72. doi: 10.1111/cei.12124

280. Rowe SE, Wagner NJ, Li L, Beam JE, Wilkinson AD, Radilinski LC, et al. Reactive Oxygen Species Induce Antibiotic Tolerance During Systemic Staphylococcus Aureus Infection. Nat Microbiol (2020) 5(2):282–90. doi: 10.1038/s41564-019-01627-y

281. Fu P, Ramchandran R, Sudhadevi T, Kumar PPK, Krishnan Y, Liu Y, et al. Nox4 Mediates Pseudomonas Aeruginosa-Induced Nuclear Reactive Oxygen Species Generation and Chromatin Remodeling in Lung Epithelium. Antioxid (Basel) (2021) 10(3):477. doi: 10.3390/antiox10030477

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Dumas and Knaus. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.